Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Phase III assessment of topotecan, cyclophosphamide and high-dose ifosfamide for refractory Ewing sarcoma patients

ASCO 2022

Published: 5 Jun 2022

Views: 111

Rating:

Save

Dr Martin McCabe- University of Manchester, Manchester, England

Dr Martin McCabe presents his study on chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES). rEECur is the first randomised controlled trial in this setting.

The primary outcome was event-free survival (EFS) for the phase III comparison. Secondary outcomes included overall survival (OS), toxicity, and quality of life (QoL).

He concludes the presentation by discussing his findings of the study.

Watch Dr McCabe's interview on the study here

Watch Dr Gralow comment on the study here

Read the news story here

Related Videos

Innovative treatments for solid tumours – TTFields as a therapeutic modality

Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic...

Innovative treatments for solid tumours – TTFields as a therapeutic modality ( Dr Giuseppe Lombardi, Dr Helen Bulbeck, Prof Dean Fennell and Dr Tadeja Urbanic-Purkart )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

The parotid gland; an unusual site of colorectal cancer metastasis

Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines

The parotid gland; an unusual site of colorectal cancer metastasis ( Dr Paula Isabel Franco - St Luke’s Medical Center, Malina, Philippines )

The advantages of IORT for early breast cancer treatment

Dr David Martinez Perez - AUNA, Lima, Peru

The advantages of IORT for early breast cancer treatment ( Dr David Martinez Perez - AUNA, Lima, Peru )

Durable effect of imatinib and metronomic chemotherapy with capecitabine in...

Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan

Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma ( Dr Sana Al-Sukhun - Al Hyatt Oncology Practice, Amman, Jordan )

The pros and cons of breast IORT and ultra hypofractionation (FR)

Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France

$The pros and cons of breast IORT and ultra hypofractionation (FR) ( Dr Sofia Rivera - Institut Gustave Roussy, Villejuif, France )$

Developments in breast reconstructive surgery

Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal

Developments in breast reconstructive surgery ( Dr Maria João Cardoso - Champalimaud Cancer Centre, Lisbon, Portugal )

Comment: LUMINA results show that women with low levels of the Ki67 biomarker...

Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA

Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Corey Wayne Speers - University of Michigan, Ann Arbor, USA )

More from ecancer